Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Sells $1,042,842.87 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High sold 29,787 shares of the stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $35.01, for a total transaction of $1,042,842.87. Following the sale, the chief operating officer now directly owns 148,792 shares of the company’s stock, valued at approximately $5,209,207.92. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Susanna Gatti High also recently made the following trade(s):

• On Monday, June 24th, Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock. The stock was sold at an average price of $35.33, for a total transaction of $359,058.79.
• On Wednesday, June 12th, Susanna Gatti High sold 40,000 shares of Dyne Therapeutics stock. The shares were sold at an average price of $33.36, for a total transaction of $1,334,400.00.
• On Monday, June 10th, Susanna Gatti High sold 80,000 shares of Dyne Therapeutics stock. The stock was sold at an average price of $30.24, for a total transaction of $2,419,200.00.
• On Thursday, May 16th, Susanna Gatti High sold 2,738 shares of Dyne Therapeutics stock. The shares were sold at an average price of $28.27, for a total value of $77,403.26.

Dyne Therapeutics Stock Up 0.0 %

DYN stock opened at $33.92 on Thursday. The firm’s 50-day simple moving average is $29.56 and its 200 day simple moving average is $24.26. The stock has a market cap of $2.96 billion, a PE ratio of -8.54 and a beta of 1.06. Dyne Therapeutics, Inc. has a fifty-two week low of $6.40 and a fifty-two week high of $36.60.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.81). Equities analysts forecast that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Institutional Trading of Dyne Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Wetzel Investment Advisors Inc. acquired a new position in shares of Dyne Therapeutics in the 1st quarter worth $28,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Dyne Therapeutics by 355.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock worth $94,000 after buying an additional 5,541 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Dyne Therapeutics by 28.0% in the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after acquiring an additional 1,291 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Dyne Therapeutics during the fourth quarter valued at approximately $172,000. Finally, Corton Capital Inc. lifted its position in shares of Dyne Therapeutics by 51.7% in the 3rd quarter. Corton Capital Inc. now owns 19,926 shares of the company’s stock valued at $179,000 after acquiring an additional 6,793 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on DYN. HC Wainwright increased their target price on Dyne Therapeutics from $36.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, May 20th. Morgan Stanley assumed coverage on shares of Dyne Therapeutics in a research report on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 price objective for the company. Piper Sandler boosted their target price on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Jefferies Financial Group upped their price objective on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, May 20th. Finally, Chardan Capital lifted their price objective on Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, May 21st. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $40.78.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.